Ignite Creation Date:
2025-12-24 @ 11:54 PM
Ignite Modification Date:
2026-01-05 @ 3:15 AM
Study NCT ID:
NCT00191451
Status:
COMPLETED
Last Update Posted:
2009-11-20
First Post:
2005-09-12
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study of Gemcitabine and Carboplatin (Plus Herceptin in Human Epidermal Growth Factor Receptor 2 Positive [HER2+] Patients) With Metastatic Breast Cancer
Sponsor:
Eli Lilly and Company
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
9397
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
None
Responsible Party Affiliation:
Old Name:
Chief Medical Officer
Old Organization:
Eli Lilly